Fintel reports that on August 4, 2023, Raymond James maintained coverage of Becton, Dickinson And (NYSE:BDX) with a Outperform recommendation.
Analyst Price Forecast Suggests 11.30% Upside
As of August 2, 2023, the average one-year price target for Becton, Dickinson And is 299.07. The forecasts range from a low of 262.60 to a high of $341.25. The average price target represents an increase of 11.30% from its latest reported closing price of 268.70.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Becton, Dickinson And is 18,961MM, a decrease of 0.45%. The projected annual non-GAAP EPS is 12.06.
What is the Fund Sentiment?
There are 2442 funds or institutions reporting positions in Becton, Dickinson And. This is a decrease of 15 owner(s) or 0.61% in the last quarter. Average portfolio weight of all funds dedicated to BDX is 0.45%, a decrease of 11.84%. Total shares owned by institutions decreased in the last three months by 1.20% to 280,601K shares. 
The put/call ratio of BDX is 0.60, indicating a bullish outlook.
What are Other Shareholders Doing?
Price T Rowe Associates holds 14,928K shares representing 5.26% ownership of the company. In it's prior filing, the firm reported owning 18,176K shares, representing a decrease of 21.76%. The firm decreased its portfolio allocation in BDX by 25.60% over the last quarter.
Wellington Management Group Llp holds 9,826K shares representing 3.46% ownership of the company. In it's prior filing, the firm reported owning 10,012K shares, representing a decrease of 1.89%. The firm decreased its portfolio allocation in BDX by 86.67% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,789K shares representing 3.09% ownership of the company. In it's prior filing, the firm reported owning 8,615K shares, representing an increase of 1.99%. The firm decreased its portfolio allocation in BDX by 8.30% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 6,625K shares representing 2.33% ownership of the company. In it's prior filing, the firm reported owning 6,593K shares, representing an increase of 0.48%. The firm decreased its portfolio allocation in BDX by 9.29% over the last quarter.
T. Rowe Price Investment Management holds 5,319K shares representing 1.87% ownership of the company. In it's prior filing, the firm reported owning 3,574K shares, representing an increase of 32.80%. The firm increased its portfolio allocation in BDX by 35.35% over the last quarter.
Becton, Dickinson And Background Information
(This description is provided by the company.)
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
Additional reading:
- BD Reports Third Quarter Fiscal 2023 Financial Results Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™ Infusion System
- Subsidiary Issuers of Guaranteed Securities
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
